Director Lawrence Sandra AJ executed a sale of 1,560 shares of Class A common stock of Sera Prognostics, Inc. (NASDAQ: SERA) on March 6, 2026, generating proceeds of $3,042. The disposition was completed at weighted average prices in the range of $1.90 to $2.00 per share. The sale was carried out under a Rule 10b5-1 trading plan that the director adopted on June 10, 2025.
Following the transaction, Lawrence Sandra AJ retains direct ownership of 18,033 shares of Sera Prognostics. At the time of the sale, the company's shares were trading at approximately $1.95, representing a decline of nearly 15% over the prior week and remaining relatively close to a 52-week low of $1.37.
Separate from the insider transaction, Sera Prognostics disclosed results from a sizable clinical trial evaluating its PreTRM Test, which assesses the risk of spontaneous preterm birth. The randomized study enrolled 5,018 women and found that when the PreTRM Test was combined with targeted interventions for those identified as high risk, the intervention group saw meaningful improvements in outcomes for newborns.
Specifically, the trial reported a 56% reduction in births occurring before 32 weeks of gestation and a 32% reduction in births occurring before 35 weeks among participants who were identified as high risk and received additional care. The supplemental care provided to high-risk participants included measures such as daily vaginal progesterone and low-dose aspirin.
Market watchers also noted a new equity research development: Jefferies has initiated coverage of Sera Prognostics with a Buy rating and a $5.00 price target, reflecting the firm’s positive view of the company’s core PreTRM Test. Additionally, a proprietary platform analysis referenced in company-related commentary characterized the stock as appearing undervalued at current levels and flagged further resources including nine additional ProTips and an expanded Pro Research Report for subscribers seeking more detailed analysis.
The juxtaposition of insider selling, recent analyst coverage, and the clinical trial publication creates a mixed set of datapoints for investors and market participants watching Sera Prognostics. The sale was modest in size relative to the director’s remaining stake, and the trial outcomes and analyst initiation represent potentially material developments for the company’s clinical and commercial narrative.
Information included in this report is limited to the transaction details, the trial outcomes as published, and the analyst coverage and valuation commentary cited above. Additional information about commercialization, regulatory timing, or broader financial implications was not provided in the source material.